rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors
Status:
Unknown status
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The study evaluates the efficacy and safety of a prophylactic treatment with recombinant
activated FVII in reducing the frequency of joint bleeds and the development of joint damage
in children with hemophilia A who develop high-titer inhibitors.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico